Technical Analysis for RLAY - Relay Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Down | Down |
Historical RLAY trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Wide Bands | Range Expansion | 6.99% | |
Oversold Stochastic | Weakness | 6.99% | |
Bullish Engulfing | Bullish | -1.66% | |
Pocket Pivot | Bullish Swing Setup | -1.66% | |
NR7 | Range Contraction | -1.66% | |
Inside Day | Range Contraction | -1.66% | |
Wide Bands | Range Expansion | -1.66% | |
Oversold Stochastic | Weakness | -1.66% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Rose Above 10 DMA | about 6 hours ago | |
Rose Above Previous Day's High | about 7 hours ago | |
10 DMA Resistance | about 7 hours ago | |
Up 10% | about 7 hours ago | |
Up 1 ATR | about 7 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Relay Therapeutics, Inc. Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Tyrosine Kinase Receptors Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Fibroblast Growth Factor Receptor 2 Metastatic Solid Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 64.0 |
52 Week Low | 32.56 |
Average Volume | 692,670 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 46.93 |
20-Day Moving Average | 47.57 |
10-Day Moving Average | 44.27 |
Average True Range | 3.82 |
ADX | 14.98 |
+DI | 16.54 |
-DI | 19.84 |
Chandelier Exit (Long, 3 ATRs ) | 51.50 |
Chandelier Exit (Short, 3 ATRs ) | 51.65 |
Upper Bollinger Band | 55.15 |
Lower Bollinger Band | 39.99 |
Percent B (%b) | 0.22 |
BandWidth | 31.87 |
MACD Line | -1.72 |
MACD Signal Line | -0.91 |
MACD Histogram | -0.8111 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 50.50 | ||||
Resistance 3 (R3) | 50.38 | 47.86 | 49.30 | ||
Resistance 2 (R2) | 47.86 | 46.02 | 47.92 | 48.90 | |
Resistance 1 (R1) | 45.57 | 44.89 | 46.72 | 45.69 | 48.50 |
Pivot Point | 43.05 | 43.05 | 43.62 | 43.11 | 43.05 |
Support 1 (S1) | 40.77 | 41.22 | 41.91 | 40.89 | 38.08 |
Support 2 (S2) | 38.25 | 40.08 | 38.31 | 37.68 | |
Support 3 (S3) | 35.96 | 38.25 | 37.28 | ||
Support 4 (S4) | 36.08 |